MacroGenics Inc. To License Novel Monoclonal Antibody Target From OriGene Technologies, Inc. For Immediate Release Rockville, MD, October 19, 2004 ROCKVILLE, Md., OCTOBER 19 -- OriGene Technologies Inc. and MacroGenics, Inc. announced today that the companies have entered into a license agreement
MacroGenics Completes Series B Financing For Immediate Release Rockville, MD, October 15, 2004 MacroGenics, Inc., a growing biotechnology company developing antibodies and vaccines to treat cancer, autoimmune disorders, and infectious diseases, announced the completion of its Series B financing of
CONTACTS: For Neose Technologies, Inc. Robert I. Kriebel - Sr. VP & CFO (215) 315-9000 Barbara Krauter - Manager (215) 315-9000 For MacroGenics Michael Richman - Exec. VP & CFO (301) 354-0681 For Immediate Release April 26, 2004 HORSHAM, Pa. , and ROCKVILLE , Md.
CONTACTS: For Genzyme Sally Curley (investors) (617) 591-7140 Dan Quinn (media) (617) 591-5849 For MacroGenics Michael Richman (301) 354-0681 For Immediate Release October 29, 2003 CAMBRIDGE, Mass. and Rockville, Md . Genzyme Corp. (Nasdaq: GENZ) and MacroGenics, Inc.
HHS Names UTMB, Seven Others as New Regional Centers To Focus on Biodefense Research The Department of Health and Human Services (HHS) today announced that the University of Texas Medical Branch at Galveston (UTMB) is among eight institutions nationwide receiving grants totaling approximately $350
MacroGenics Announces Senior Appointments Rockville, MD April 1, 2002 - MacroGenics, Inc., a biotechnology company that is developing immunotherapeutics for treating cancer and inflammatory diseases, announced two key appointments to the senior management team. Michael S.
Former MedImmune Senior Vice President joins MacroGenics; Company completes key license agreements and closure of second tranche of Series A financing, bringing total raised to $13.5MM.